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fDepartment of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlandsa b s t r a c tBoth chronic obstructive pulmonary disease (COPD) and sudden cardiac death (SCD) are major health burdens. A number of studies have
addressed their interrelationship, but currently no systematic review has been published. Our objective is to give an overview of the literature of
the association between COPD and SCD. A search on PubMed with both MeSH headings and free-text keywords was performed. We selected all
original articles of studies in humans that assessed COPD on the one hand and SCD, electrocardiographic markers for SCD, ventricular
arrhythmias, or asystole on the other. The electronic search yielded 251 articles, from which 27 full publications were selected after careful
evaluation of the full-text articles. In these studies, COPD was associated with a prolonged and shortened QT interval. In patients with a
myocardial infarction (MI), COPD was associated with an increased risk of ventricular arrhythmias and decreased survival. COPD was a risk
factor for SCD both in cardiovascular patient groups and in community-based studies, independent from cardiovascular risk proﬁle. Studies of
the potential impact of respiratory treatment on the occurrence of SCD showed conﬂicting results. In conclusion, cumulating evidence
associates COPD with an increased risk of SCD. Asystole and pulseless electric activity could be more common than VT/VF in deaths associated
with COPD. Underlying mechanisms explaining this association require further investigation.
Key words: COPD, Sudden cardiac death, Ventricular arrhythmia, Cardiac arrest.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Cardiovascular disease is the leading cause of death and
imposes a large global burden of morbidity and morta-
lity [1–4]. About half of all cardiovascular deaths are
sudden cardiac deaths (SCDs). SCDs occur suddenly and1016/j.tcm.2016.04.001
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SCD remains a major cause of death, even though the
incidence seems to be decreasing in Western Europe [2,7].
The majority of SCDs is thought to result from ventricular
arrhythmias [8]. However, in recent years the proportion of
SCDs resulting from pulseless electrical activity (PEA) andpen access article under the CC BY license
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ment of coronary heart disease (CHD) and increased use
of an implantable cardioverter deﬁbrillators (ICDs) [10]. SCD
can be the result of a variety of underlying causes, such as
CHD [11], cardiomyopathies [12], or use of QT-prolonging
drugs [13]. However, many possible etiologies have not been
established [6].
Chronic obstructive pulmonary disease (COPD) is the third
leading cause of death globally [4]. Progressive airﬂow limi-
tation is the hallmark of COPD. Progressive airﬂow limitation
is associated with a local chronic inﬂammatory response in
the airways and lungs [14], but in a subgroup of patients with
COPD biomarkers of systemic inﬂammation (e.g., ﬁbrinogen
and C-reactive protein) are also increased [15–17]. COPD and
cardiovascular disease are notably linked. For example, ECG
abnormalities such as bundle branch blocks and axis devia-
tions are common in COPD patients [18]. COPD patients also
have a higher rate of cardiovascular morbidity and mortality
than the general population [19]. Moreover, half of the
deaths of COPD patients are attributable to cardiovascular
disease [19]. The association of COPD with cardiovascular
disease in general suggests that there could also be an
association between COPD and SCD. Indeed, COPD can cause
respiratory arrest, which can lead to PEA and asystole, and
ultimately SCD. Accurate prediction of SCD in the general
population is still a challenge because most cases of SCD
occur in people with seemingly low cardiovascular risk [6].
Thus, risk assessment of SCD might be improved by studying
the link between COPD and SCD. Studying the association of
COPD with SCD includes assessing possible common risk
factors (e.g., ageing or smoking) and the effect of respiratory
drugs on SCD risk. To date, there has not yet been a
systematic review of the literature that has studied the
association of COPD with SCD. The objective of this article
is to provide an overview of the published literature on this
association.Fig. 1 – An overview of the electronic search and selection
process. Abbreviations—COPD: chronic obstructive
pulmonary disease, SCD: sudden cardiac death, VT/VF:
ventricular tachycardia/ventricular ﬁbrillation.Methods
We searched PubMed from inception until December 10, 2015
using a combination of MeSH terms and free-text keywords.
For COPD we used the MeSH term “Pulmonary Disease,
Chronic Obstructive.” The free-text keywords were all terms
derived from COPD and pulmonary emphysema, including
the terms “obstructive pulmonary disease” and “COPD.” For
SCD we used the MeSH terms “Death, Sudden, Cardiac,”
“Heart Arrest,” “Tachycardia, Ventricular,” “Ventricular Fibril-
lation,” “Ventricular Flutter,” and “torsades de pointes.” Free-
text keywords for SCD were all derived from these MeSH
terms. In order to retrieve unindexed articles we searched
without additional ﬁlters for the publication dates after 2014.
After that, we ﬁltered our search results on articles written
in English and on human participants aged older than
18 years. The online supplement contains the complete
search strategy, including all MeSH terms and free-text key-
words. Citation lists of the publications found by the elec-
tronic search were handsearched for additional relevant
publications.Articles were deemed relevant for this review if they
contained original research, included COPD patients or lung
function measurements and the outcome SCD, ventricular
arrhythmias, or electrocardiographic (ECG) markers for SCD.
We extracted relevant articles from the list of the initial
search in a two-step process. In the ﬁrst step, two reviewers
(M.v.d.B. and L.L.) independently screened the abstracts of the
list of articles. Disagreements in abstract selection were
resolved with consensus meetings. In the second step, the
full-text articles were retrieved and all relevant information
was extracted and tabulated. Based on this, a ﬁnal selection
was made.Results
General ﬁndings
The electronic search on PubMed yielded 251 publications. An
additional ﬁve publications were found by hand-searching
citation lists. After screening the abstracts, we included 27
publications for reviewing. The selection process and its
results are shown in more detail in Fig. 1. The selected
articles included 26 observational studies (10 cohort studies,
9 cross-sectional studies, and 7 case–control studies) and one
randomized controlled clinical trial (RCT). A list with sum-
maries of all included articles is provided in Supplementary
Table 1.
The results section consists of two parts. Part one
addresses the association of COPD with SCD, ventricular
arrhythmias, and ECG markers for SCD. First, we review
COPD and electrocardiographic markers associated with
SCD. Then, we review publications addressing COPD, ven-
tricular arrhythmias, and cardiac arrest; and provide an
overview of studies addressing COPD and SCD in patient
cohorts and community-based studies. In part two, we
T R E N D S I N C A R D I O V A S C U L A R M E D I C I N E 2 6 ( 2 0 1 6 ) 6 0 6 – 6 1 3608discuss potential sex differences in the association between
COPD and SCD. Finally, we focus on possible mechanisms
underlying the association of SCD and COPD, including
smoking, hypertension, respiratory drugs, and the role of
COPD exacerbations.Part one: Association of COPD with SCD,
ventricular arrhythmias, and ECG markers for SCD
COPD and electrocardiographic markers of SCD
The heart rate corrected QT (QTc) interval is a known risk
factor for SCD [20], and it was the most commonly used ECG
marker in the studies we found. In the study by Zulli et al.
[21], QTc prolongation was associated with an increased
mortality risk in a cohort of 246 COPD patients [21]. The
association of COPD with the QTc interval was addressed in
four studies, with mixed results—Tukek et al. [22] (total
n ¼ 73) and Sievi et al. [23] (n ¼ 164) found that QTc was
signiﬁcantly higher in COPD cases compared with controls
[22,23], but the study by Lahousse et al. [24], which compared
1615 COPD patients with all other participants (n ¼ 11,856) at
baseline, and Zupanic et al. (n ¼ 62) [25] did not ﬁnd a
signiﬁcant difference. However, Lahousse et al. [24] only
compared the median QTc of COPD patients to participants
without COPD at baseline and the study by Zupanic et al. [25]
was possibly underpowered. A ﬁfth study by Yildiz et al. [26],
measured the maximum QT interval without heart rate
correction on 24-h Holter recordings. This study found that
the uncorrected maximum 24-h QT interval was signiﬁcantly
higher in COPD patients [26].
An abnormally short QT interval (r300 ms) has also been
associated with SCD [27]. A large cross-sectional population-
based study found that although QT shortening was rare
(incidence of 2.7 per 100,000 persons), it was signiﬁcantly
associated with COPD with an odds ratio (OR) of 2.4 (95% CI:
1.3–3.5) [28]. This study included 6,547,785 ECGs of which
660,534 were recorded in COPD patients [28].
In addition to the QTc interval, heart rate variability has
also been associated with SCD [29]. Heart rate variability was
assessed next to the QTc interval by Tukek et al. [22], Yildiz
et al. [26], and Zupanic et al. [25] These studies found that
heart rate variability was signiﬁcantly decreased in COPD
patients [20,21,23]. A reduced heart rate variability is indica-
tive of an increased sympathetic tone and a reduced vagal
tone, which might be pathways from COPD to an increased
SCD risk [30].
QT dispersion (QTD) is the difference between the longest
and shortest QT interval in any lead for a given set of ECG
leads [31]. QTD has been challenged on the ground that it is
only a derivative attribute of T-loop morphology and not
indicative of repolarization instability, and therefore an
unsound marker for the prediction of ventricular arrhythmias
[31,32]. Nevertheless, four studies addressed this marker
[21–23,26]. In the study by Sievi et al. [23], QTD was not
signiﬁcantly increased in COPD patients compared with
controls matched for age, cardiovascular risk, and medica-
tion use, but it was increased in COPD patients in Tukek
et al. [22] and Yildiz et al. [26] Finally, in the cohort study ofZulli et al. [21], an increased QTD was associated with higher
mortality risk [21].
COPD, ventricular arrhythmias, and cardiac arrest
Between 30% and 70% of SCD cases result from ventricular
tachycardia and ventricular ﬁbrillation (VT/VF) [9,10]. For this
reason, the association of COPD with ventricular arrhythmias
can be relevant for the association of COPD with SCD. Two
studies addressed the underlying rhythm of COPD patients
with a cardiac or a respiratory arrest. First, a study [33] in 70
patients with chronic airway obstruction admitted for acute
respiratory failure noted that 15 patients (21.4%) developed
cardiac arrest (which included VF and asystole), and four
patients (5.7%) developed VT [33]. In a cross-sectional study
(n ¼ 5415) [34] of people who were resuscitated for out-of-
hospital cardiac arrests (OHCAs), 20% of OHCAs were judged
to be caused by COPD based on case history. The initial
rhythm of resuscitation differed between the causes of the
OHCAs—for the OHCAs with a cardiac cause, the initial
rhythm was VT/VF in 48% of the cases, and PEA or asystole
in 50% of the cases. For the OHCAs caused by COPD, the initial
rhythm was VT/VF in 8% of the cases, and PEA or asystole in
88% of the cases [34]. These studies indicate that the occur-
rence of VT/VF in COPD patients is relatively low and PEA
might be more frequently associated with SCD in COPD
[33,34]. Furthermore, there was no signiﬁcant increase of
sustained VTs on a 24-h ECG in stable COPD patients after
adjustment for cardiovascular risk factors [35]. In patients
with a non–ST-segment elevation myocardial infarction (non-
STEMI), the association of COPD with VT/VF seems to be
stronger—in 26,416 patients with a non-STEMI, a history of
COPD was associated with a signiﬁcantly increased risk of VT
(HR ¼ 1.9, 95% CI: 1.1–3.1) and VF (HR ¼ 2.5, 95% CI: 1.6–4.1)
[36]. In addition to this, one study found that after an OHCA
with VT/VF, 30-day survival was signiﬁcantly lower in COPD
patients [37].
COPD and SCD in cohorts of patient populations
Almost all studies deﬁned SCD ﬁrst as a witnessed unex-
pected death within 1 h of onset of abrupt change in symp-
toms and second as an unwitnessed death within 24 h of the
last observation as medically stable. Supplementary Table 1
shows the deﬁnitions of SCD for all included studies.
A study in 5992 COPD patients reported that 7.7% of all
deaths were SCDs [38], while a study of non-traumatic
prehospital SCDs (deﬁned as death within 1 h post-ER arrival,
n ¼ 905) found that COPD was relatively common in those
SCD cases (11% had COPD) [39]. However, neither study had a
control group (non-COPD patients and non-SCD deaths,
respectively).
Studies in patient groups with cardiac diseases found that
COPD as comorbidity is a risk factor for SCD. These clinic-
based cohorts included patients who survived percutaneous
coronary interventions (PCIs, n ¼ 6846) [40] and coronary
artery bypass graft (CABG, n ¼ 2910) [40] and patients with
atrial ﬁbrillation (AF, n ¼ 334) who underwent atrioventricular
node ablation [41]. However, COPD was not a signiﬁcant risk
factor for SCD in a study in elderly patients (n ¼ 3726, mean
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replacement (TAVR) [42].
Patients with an ICD are a special patient group for the
study of ventricular arrhythmias and SCD. COPD was a risk
factor for appropriate ICD shocks, which indicate the occur-
rence of ventricular arrhythmias in a cohort study of patients
with an ICD (n ¼ 628) [43]. A second cohort study (n ¼ 202)
found that COPD was also associated with ICD shocks, but
this study did not differentiate appropriate from inappropri-
ate ICD shocks (due to non-ventricular arrhythmias) [44].COPD and SCD in community-based studies
Three community-based studies investigated the association
of SCD or SCA with COPD. First, SCA risk was increased in
COPD patients (OR ¼ 1.4, 95% CI: 1.2–1.6), in a case–control
study that compared SCA patients with VT/VF (n ¼ 1310) to
controls matched for age, sex, and index date (n ¼ 5793). This
study adjusted for cardiovascular risk factors, which were
estimated by the use of cardiovascular drugs [45]. Second,
COPD was a risk factor for SCD in a population-based cohort
of middle-aged and elderly participants (HR ¼ 1.4, 95% CI: 1.0–
1.5). This study additionally created competing risk models,
which showed that COPD is a risk factor for SCD beyond the
generalized increased risk of death in COPD patients [24].
Third, a higher frequency of respiratory diseases (interna-
tional classiﬁcation of diseases 10—group J which includes
COPD) was observed in SCA patients. However, this was not
statistically signiﬁcant (p ¼ 0.184). In this study, a large cross-
sectional study of emergency medical service interventions,
the medical records on comorbid conditions of patients with
out-of-hospital sudden cardiac arrest (SCA, n ¼ 245) were
examined retrospectively and compared with patients that
underwent interventions for other reasons (n ¼ 26,398) [46].
The fact that the higher frequency of respiratory diseases was
not signiﬁcant could be explained by the lack of speciﬁc COPD
phenotyping or by the underdiagnosis of COPD in the medical
records of emergency operations.Part two: Sex differences and mechanisms of the
association of SCD and COPD
Sex differences in the association of COPD with SCD
Three studies analyzed sex differences as possible effect
modiﬁers of the association between COPD and VT/VF or
SCD. First, men were more prone to VT than women in a
cross-sectional study of ambulatory ECGs of 69 COPD patients
[47]. In contrast, there was no sex difference in the risk of SCA
between participants with COPD or asthma and participants
without COPD or asthma in a study of SCA cases (n ¼ 1568)
[48]. Third, SCD occurred more frequently in men with COPD
in the population-based study of Lahousse et al. [24] with
13,471 community-dwelling participants. However, this study
found that frequent COPD exacerbations carried a slightly
higher risk for women (HR ¼ 3.5, 95% CI: 1.8–6.8) than for
men (HR ¼ 3.1, 95% CI: 1.7–5.5) [24]. Since the risk increased
further when restricted to post-menopausal women, a role ofstress-induced cardiomyopathy during COPD exacerbations
was suggested [24].
Smoking
The association of COPD with SCD was adjusted for smoking
in two cohort studies. The ﬁrst cohort study (total n ¼ 7441)
found that low FEV1 and FVC were associated with SCD both
in smokers and non-smokers [15], and the study by Lahousse
et al. [24] reported that the association between COPD and
SCD was independent of smoking behavior. Moreover, smok-
ing was not a signiﬁcant predictor for ICD shocks in a study
in a cohort of patients with ICDs [44]. These studies suggest
that the association of COPD and SCD is independent of
smoking.
Hypertension and timing of SCA/SCD
Two studies assessed factors associated with both COPD and
cardiac endpoints [myocardial infarction (MI) or OHCA]. First,
hypertension—acute MI patients admitted to the ICU with
hypertension more often had COPD than normotensive MI
patients, but they presented less often with VF [49]. Second,
the time of incidence—nighttime admissions for OHCAs more
often had COPD as comorbidity, and lower 1-year survival
[49]. Furthermore, in the study by Lahousse et al. [24], SCDs in
COPD patients occurred more often at night than SCDs in
non-COPD patients (53% vs. 36%) [24]. The increased number
of ventricular ectopic episodes during sleep could be the
result of reduced ventilation and a blunted response to
hypercapnia [50,51].
Respiratory drugs
The study by Warnier et al. [45] reported that use of inhaled
short-acting beta-agonists (SABAs) and use of inhaled mus-
carinic antagonists (the study did not specify if these were
long-acting or short-acting anticholinergics) were associated
with sudden cardiac arrest (SCA) due to VT/VF. The OR for
SABAs was 3.9 (95% CI: 1.7–8.8) and for anticholinergics 2.7
(95% CI: 1.5–4.8), after adjustment for concomitant cardiovas-
cular disease. Use of inhaled corticosteroids was not associ-
ated with SCA in this study [45]. However, increased drug use
during exacerbations or increased drug use due to more
severe COPD might be plausible confounders for the
increased risk of SCA in users of SABAs and anticholinergics
[52]. In contrast, two studies found no effect of respiratory
drugs on the risk of SCD in COPD. First, use of the long-acting
anticholinergic tiotropium did not increase the risk of VT/VF
in a meta-analysis combining 30 clinical trials and including
19,545 COPD patients [53]. However, because there were only
ﬁve fatal VT/VF cases, this meta-analysis was underpowered
for this endpoint [53]. Clinical trials of COPD patients possibly
have a low incidence of VT/VF due to the selection of
relatively stable patients without signiﬁcant cardiovascular
comorbidities [54]. Second, use of sympathomimetic respira-
tory drugs did not signiﬁcantly interact with COPD on the risk
of SCD in the study by Lahousse et al. [24], but this study did
not take duration of drug use or dosage into account.
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In the study by Lahousse et al. [24], long-term COPD patients
with frequent exacerbations had a higher risk of SCD (HR ¼
3.2, 95% CI: 2.1–5.0) than long-term COPD patients without
frequent exacerbations (HR ¼ 1.52, 95% CI: 1.1–2.2). Exacer-
bations only increased the risk of SCD in those participants
with elevated systemic inﬂammation at cohort entry, indicat-
ing that the association of COPD exacerbations with SCD is at
least partially mediated by systemic inﬂammation. Thus,
severity and duration of COPD are of importance for the risk
of SCD [24].Discussion
The majority of the studies support the hypothesis that COPD
is associated with SCD. COPD was a risk factor for SCD
independent of cardiovascular risk proﬁle, both in cohorts
of cardiovascular patients and in community-based studies.
Evidence for the association of COPD with VT/VF is much
weaker, and the evidence for the potential impact of respira-
tory treatment on the onset of SCD is inconclusive. COPD was
also associated with reduced heart rate variability, while the
studies for QTc prolongation were inconclusive.
There are several theoretical explanations for an associa-
tion between COPD and SCD, which are illustrated in Fig. 2.
We will review each of these mechanisms and note what has
been studied, and identify gaps needing further research.
First, COPD might cause pathophysiological changes thatFig. 2 – Possible mechanisms of the association between
COPD and SCD. Note: Besides potential misclassiﬁcation,
COPD exacerbations are known to amplify both
cardiovascular pathophysiology and the use of respiratory
drugs. Abbreviations—COPD: chronic obstructive pulmonary
disease, SCD: sudden cardiac death.directly increase the risk of SCD. Examples of previously
studied pathological changes in COPD are changes in cardiac
repolarization, represented by QT or QTc interval abnormal-
ities [22–26,28], and increased sympathetic tone or reduced
vagal tone indicated by a reduced heart rate variability
[22,25,26]. Other studies have also found that COPD is asso-
ciated with baroreceptor sensitivity abnormalities [55], heart
rate variability abnormalities [56], and a direct increase in
muscle sympathetic nerve activity [57]. Further research
might focus on the interaction of COPD and autonomic
neuropathy for the risk of SCD. The evidence for the associ-
ation of COPD with QTc interval prolongation was inconclu-
sive, and QT interval variability, a promising ECG marker of
ventricular arrhythmias and SCD [58], has not yet been
studied in COPD. Therefore, QT variability might be an
avenue for future research. Besides ECG markers, the effect
of systemic inﬂammation in COPD on the risk of SCD has
been assessed [24]. However, there are also a number of
pathophysiological changes associated with COPD that have
not yet been studied in relation to SCD risk, including hypoxia
and hypoxemia [14], cardiac ischemia [8,19], heart failure [59],
and possibly pulmonary hyperinﬂation and pulmonary
hypertension [24].
Second, there may be common risk factors acting as
confounders. The association of COPD with SCD was inde-
pendent of smoking, which was addressed in two studies
[15,24]. The role of common genetic risk factors needs to be
elucidated, since these studies will provide more insights into
common pathogenic pathways that lead to increased SCD
risk in COPD (e.g., systemic inﬂammation or tissue remodel-
ing). No study to date has assessed common genetic risk
factors between COPD and SCD.
Third, use of respiratory drugs could be associated with
SCD. The studies included in this review give contradictory
results and no study assessed the dose–response relationship
of respiratory drugs and SCD [24,45,53]. The TIOSPIR [60] and
SUMMIT [61] randomized controlled trials were not included
in our review because they have not (or not yet) reported on
the endpoint SCD. Because the association of respiratory
drugs with SCD risk is probably dose dependent, future
studies should address the dose effect. In addition to inhaled
COPD drugs, none of the included studies have addressed the
oral macrolide antibiotics, which are often prescribed for
COPD exacerbations. These antibiotics are known QT-
prolonging drugs, and suspected of increasing the risk of
ventricular arrhythmias and SCD [20,62].
Fourth, the diagnosis of COPD could change the prescrip-
tion pattern of cardiovascular drugs. On the one hand,
contra-indications for drugs like beta-blockers might lead to
inadequate cardiovascular prevention, which might increase
the risk of SCD. On the other hand, the medical attention that
is sought for COPD may also lead to improved cardiovascular
prognosis by active prevention of cardiovascular risks (such
as smoking and hypertension). Warnier et al. [45] studied the
prevalence of use of cardiovascular drugs in SCD cases and
controls, but did not assess the interaction with COPD.
Therefore, a time-dependent and dose-dependent assess-
ment of individual cardiovascular drugs in COPD patients
and non-COPD patients, and the associated SCD risk, is
needed.
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misclassiﬁcation of acute respiratory deaths as sudden car-
diac deaths especially when non-witnessed. However, the
ratio of witnessed to non-witnessed SCD was not different for
participants with COPD compared with participants without
COPD in the largest study of the association between COPD
and SCD [24].
Lastly, the occurrence of a higher rate of exacerbations has
also been reported to increase the risk of SCD in COPD
patients [24]. Among explanatory mechanisms recently
reviewed [52], this association can be caused by a direct
increase in systemic inﬂammation associated with frequent
exacerbations [63], or indirectly by use (and abuse) of SABAs
and LABAs. Excessive use of SABAs and LABAs may lead to
hypomagnesemia [64], which has also been associated with
an increased risk of SCD [65].
A strength of the studies addressing SCD is the uniform
deﬁnition of SCD as a witnessed unexpected death within 1 h
of onset of abrupt change in symptoms or an unwitnessed
death within 24 h of the last observation as medically stable.
However, none of the studies with the endpoint SCD reported
the preceding cardiac arrhythmia. Therefore, we were unable
to distinguish between SCD caused by VT/VF and SCDs
resulting from PEA and asystole. One study indicates that
PEA and asystole are more common than VT/VF in COPD
patients with cardiac arrest [34]. As these different direct
causes of SCD are possibly the results of different pathologies
and associated with different risk factors, this is a limitation
of the studies included in this review.
In conclusion, accumulating evidence associates COPD
with an increased risk of SCD. Asystole and PEA could be
more common than VT/VF in COPD-associated deaths.
Underlying mechanisms explaining this association require
further investigation. Promising avenues of further research
include studies of QT variability and hypoxia, genetic studies
and pharmaco-epidemiological studies.Appendix A. Supplementary Information
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.tcm.2016.
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